Fanny Abouzeid is an associate in the Brussels office of White & Case and a member of the Firm’s EU law practice group. Her practice focuses on European and French competition law, including antitrust and merger control. Her expertise includes working on complex international mergers, cartel investigations, abuse of dominance cases, and advising on competition law matters related to horizontal and vertical agreements. Fanny assists clients in proceedings before the European Commission and EU courts. Fanny also has experience in broader matters of EU law, notably in EU internal market law and EU regulatory law, including in the fields of chemicals, energy and electrical and electronic equipment. Prior to joining White & Case, Fanny worked in the antitrust and competition departments of other international law firms in Brussels and Paris. Fanny holds an LLM from the College of Europe and Master of Laws degrees from the University Paris I Panthéon-Sorbonne and the University Paris II Panthéon-Assas. She also has a diploma in economics and business from the College de Droit of University Paris II Panthéon-Assas.
665
In its judgments of March 9, 2023 the Court of Justice of the EU (CJEU) annulled the General Court’s (GC) judgment that had partly upheld the European Commission’s (EC) inspection decision, and ruled that the EC had failed to fulfil its obligation to properly record the interviews it conducted (...)
254
Competition authorities have been traditionally reluctant to pursue excessive pricing cases since many of them had failed on the facts. However, in recent years, there has been a resurgence of the topic in pharma-related cases. In particular, the national competition authorities have led the (...)
177
While there is still no standalone foreign direct investment (FDI) screening at the EU level, the EU continues to push for a coordinated approach toward foreign direct investments into the EU. The key instrument is the EU Screening Regulation, which has entered into force on October 11, 2020. (...)
112
On 9 September 2020, the French Competition Authority (FCA) imposed fines totalling €444 million on three laboratories (Novartis, Roche and Genentech) for having abused their collective dominant position in the market for the treatment of age-related macular degeneration (AMD). The facts that (...)
19 avenue Jean Aicard
75011 Paris, France
106 West 32nd Street, Suite 149
New York, NY, 10001, USA
563 Chiswick High Road
W4 3AY London, UK
